FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791436202> ?p ?o ?g. }

• W2791436202 abstract "Objective:The first interferon-free regimen became available in Russia in 2015. It brought hope to HCV Gt1 patients with cirrhosis for whom interferon-based schemes found to be non-effective or contraindicated. 3D therapy was the only available etiotropic option for them. New safety data published after the start of our study significantly limited usage of this regimen among patients with non-compensated cirrhosis. The aim of this study was to evaluate efficacy and safety of the 3D interferon-free regimen among HCV Gt1b patients with non-compensated cirrhosis.Method:66 patients (26 males and 40 females) with HCV Gt1b and non-compensated cirrhosis were enrolled. All of them were treated with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin for 12 weeks. Ribavirin was discontinued after 4 weeks of therapy due to onset of new data on the efficacy of 3D regimen without ribavirin in Turquoise III study published in September 2015 before the change of package insert. Child-Pugh score was assessed before the start of antiviral therapy as follows: 21 patients (31,8%) – 9 points, 11 patients (16,7%) – 8 points, 34 patients (51,5%) – 7 points. The key method used to evaluate study results was modified intent-to-treat (mITT) analysis because number of analyzed patients within treatment period changed after withdrawal caused by safety reasons but followed by assessment of efficacy among patients who discontinued treatment. Per protocol (PP) method was also used in addition to mITT.Results:Aviremia after 14 days of treatment was reached among 35 out of 65 patients (53,8%), rapid virologic response – among 79,7% patients (51/64). Each patient who received full 12-week course of treatment (n=60) including those who discontinued due to safety reasons (n=3) between 14th and 30th days of therapy reached SVR12 and SVR24. Assessment of Child-Pugh score in 6 months after EOT demonstrated decrease by 3-4 points among 21 patients (33,9%) and by 1-2 points among 35 patients. 66,1% patients reached clinical improvement in MELD score. Treatment discontinuation was caused by progression of hepatic encephalopathy and/or jaundice (4 cases). Those adverse events regressed among majority of patients after discontinuation of therapy. 3 deaths were reported (bacterial endocarditis, progression of hepatic encephalopathy and bleeding from gastric ulcers) during treatment period and 1 death in follow-up period due to progression of hepatocellular carcinoma.Conclusion:3D therapy was effective in 100% patients (mITT) with HCV GT1b and non-compensated cirrhosis both among those who completed full therapy course and those who discontinued the therapy due to safety reasons. Safety analysis demonstrated that the rate of severe adverse events was comparable with natural course of HCV-infection in patients on non-compensated cirrhotic stage without antiviral treatment." @default.
• W2791436202 created "2018-03-29" @default.
• W2791436202 creator A5011463951 @default.
• W2791436202 creator A5012629118 @default.
• W2791436202 creator A5017512144 @default.
• W2791436202 creator A5020493584 @default.
• W2791436202 creator A5030437694 @default.
• W2791436202 creator A5040507069 @default.
• W2791436202 creator A5068736837 @default.
• W2791436202 creator A5081799077 @default.
• W2791436202 date "2018-03-16" @default.
• W2791436202 modified "2023-09-24" @default.
• W2791436202 title "Evaluation of efficacy and safety of interferon-free “3D” regimen among patients with non-compensated cirrhosis caused by HCV genotype 1b infection" @default.
• W2791436202 doi "https://doi.org/10.29333/ejgm/84989" @default.
• W2791436202 hasPublicationYear "2018" @default.
• W2791436202 type Work @default.
• W2791436202 sameAs 2791436202 @default.
• W2791436202 citedByCount "1" @default.
• W2791436202 countsByYear W27914362022018 @default.
• W2791436202 crossrefType "journal-article" @default.
• W2791436202 hasAuthorship W2791436202A5011463951 @default.
• W2791436202 hasAuthorship W2791436202A5012629118 @default.
• W2791436202 hasAuthorship W2791436202A5017512144 @default.
• W2791436202 hasAuthorship W2791436202A5020493584 @default.
• W2791436202 hasAuthorship W2791436202A5030437694 @default.
• W2791436202 hasAuthorship W2791436202A5040507069 @default.
• W2791436202 hasAuthorship W2791436202A5068736837 @default.
• W2791436202 hasAuthorship W2791436202A5081799077 @default.
• W2791436202 hasBestOaLocation W27914362021 @default.
• W2791436202 hasConcept C126322002 @default.
• W2791436202 hasConcept C142462285 @default.
• W2791436202 hasConcept C203014093 @default.
• W2791436202 hasConcept C2522874641 @default.
• W2791436202 hasConcept C2776408679 @default.
• W2791436202 hasConcept C2776455275 @default.
• W2791436202 hasConcept C2777100407 @default.
• W2791436202 hasConcept C2777214474 @default.
• W2791436202 hasConcept C2778785139 @default.
• W2791436202 hasConcept C2778867932 @default.
• W2791436202 hasConcept C2779298103 @default.
• W2791436202 hasConcept C2780040827 @default.
• W2791436202 hasConcept C2781413609 @default.
• W2791436202 hasConcept C2993143319 @default.
• W2791436202 hasConcept C71924100 @default.
• W2791436202 hasConcept C90924648 @default.
• W2791436202 hasConceptScore W2791436202C126322002 @default.
• W2791436202 hasConceptScore W2791436202C142462285 @default.
• W2791436202 hasConceptScore W2791436202C203014093 @default.
• W2791436202 hasConceptScore W2791436202C2522874641 @default.
• W2791436202 hasConceptScore W2791436202C2776408679 @default.
• W2791436202 hasConceptScore W2791436202C2776455275 @default.
• W2791436202 hasConceptScore W2791436202C2777100407 @default.
• W2791436202 hasConceptScore W2791436202C2777214474 @default.
• W2791436202 hasConceptScore W2791436202C2778785139 @default.
• W2791436202 hasConceptScore W2791436202C2778867932 @default.
• W2791436202 hasConceptScore W2791436202C2779298103 @default.
• W2791436202 hasConceptScore W2791436202C2780040827 @default.
• W2791436202 hasConceptScore W2791436202C2781413609 @default.
• W2791436202 hasConceptScore W2791436202C2993143319 @default.
• W2791436202 hasConceptScore W2791436202C71924100 @default.
• W2791436202 hasConceptScore W2791436202C90924648 @default.
• W2791436202 hasLocation W27914362021 @default.
• W2791436202 hasOpenAccess W2791436202 @default.
• W2791436202 hasPrimaryLocation W27914362021 @default.
• W2791436202 hasRelatedWork W1996227777 @default.
• W2791436202 hasRelatedWork W2066045407 @default.
• W2791436202 hasRelatedWork W2076277829 @default.
• W2791436202 hasRelatedWork W2120204570 @default.
• W2791436202 hasRelatedWork W2120733999 @default.
• W2791436202 hasRelatedWork W2167780095 @default.
• W2791436202 hasRelatedWork W2420834323 @default.
• W2791436202 hasRelatedWork W263641189 @default.
• W2791436202 hasRelatedWork W2784719900 @default.
• W2791436202 hasRelatedWork W2793060991 @default.
• W2791436202 hasRelatedWork W2885054554 @default.
• W2791436202 hasRelatedWork W2901390919 @default.
• W2791436202 hasRelatedWork W2911885584 @default.
• W2791436202 hasRelatedWork W2915264331 @default.
• W2791436202 hasRelatedWork W2969850716 @default.
• W2791436202 hasRelatedWork W2982819257 @default.
• W2791436202 hasRelatedWork W3028592195 @default.
• W2791436202 hasRelatedWork W3034058671 @default.
• W2791436202 hasRelatedWork W3161339015 @default.
• W2791436202 hasRelatedWork W68438428 @default.
• W2791436202 isParatext "false" @default.
• W2791436202 isRetracted "false" @default.
• W2791436202 magId "2791436202" @default.
• W2791436202 workType "article" @default.